The high-risk group stands out because of a poor anti-tumor response (HLA-DR and CXCL13 downregulation) and low immune infiltrate content of the five biomarkers in the TME, which result in immune system evasion, favor tumor growth and progression, and lead to poor survival and RFS rates. This evidence concerns the gene CXCL13 and neoplasm.